Celldex Therapeutics (CLDX) EBIT Margin Growth (3y) (2013 - 2026)

Celldex Therapeutics (CLDX) EBIT Margin Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin Growth (3y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 9,942.00
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 530.00
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -1,211.00
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 7,794.00
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Celldex Therapeutics 2.34 Bn 2.34 Bn -1.44 Mn -55.95 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -55.95 Mn
Dec 31, 2025 -7.03 Mn
Jun 30, 2025 1.36 Mn
Mar 31, 2025 433,890.00
Dec 31, 2024 132,157.00
Sep 30, 2024 1.20 Mn
Jun 30, 2024 -146,796.00
Mar 31, 2024 -2.36 Mn
Dec 31, 2023 -49,837.00
Sep 30, 2023 -57,145.00
Jun 30, 2023 -757,425.00
Mar 31, 2023 -264,308.00
Dec 31, 2022 -26,439.00
Sep 30, 2022 -463,568.00
Jun 30, 2022 -2.06 Mn
Mar 31, 2022 -1.21 Mn
Dec 31, 2021 -540,258.00
Sep 30, 2021 -1.28 Mn
Jun 30, 2021 22,447.00
Mar 31, 2021 51,286.00